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We investigated the effects of soy isoflavone intake on breast cancer in a prospective study of 35303 Singapore Chinese women
enrolled during April 1993 to December 1998 in the Singapore Chinese Health Study. At recruitment, each subject was personally
administered a validated semiquantitative food frequency questionnaire covering 165 food and beverage items. As of December 31
2005, 629 had developed breast cancer following an accumulation of 338242 person-years. Using Cox regression and adjusting for
age at interview, year of interview, dialect group, education, family history of breast cancer, age when periods became regular, parity,
menopausal status, body mass index (BMI), n-3 fatty acid, and other covariates, we found breast cancer risk was reduced significantly
in association with high soy intake. Relative to women with lower (below median) soy intake (o10.6mg isoflavone per 1000Kcal),
women with higher (above median) intake showed a significant 18% risk reduction (relative risk (RR)¼0.82, 95% confidence interval
(CI)¼0.70–0.97). This inverse association was apparent mainly in postmenopausal women (RR¼0.74, 95% CI¼0.61–0.90), and
was not observed in premenopausal women (RR¼1.04, 95% CI¼0.77–1. 40). Among postmenopausal women, the soy–breast
cancer association was stronger in those above median BMI (RR¼0.67, 95% CI¼0.51–0.88) than in leaner women (RR¼0.83, 95%
CI¼0.62–1.11). Duration of follow-up modified the soy–breast cancer association, the effect being twice as large among women
with 10þ vs fewer years of follow-up. Neither oestrogen nor progesterone receptor status of the tumours materially influenced the
association. These prospective findings suggest that approximately 10mg of isoflavones per day, obtained in a standard serving of
tofu, may have lasting beneficial effects against breast cancer development.
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Of at least 28 detailed studies of soy and breast cancer risk
published in English since 1990, 14 were in western populations
with very low intake of soy (o1mg of isoflavone per day) and in
these, intake was unrelated to breast cancer risk (Wu et al, 2008).
Of the other 14 studies in Asia or in Asian–Americans
with substantially higher soy intake, eight (Lee et al, 1991;
Dai et al, 2001; Yamamoto et al, 2003; Hirose et al, 2005;
Lee et al, 2005; Shannon et al, 2005; Do et al, 2007) covered the
main sources of soy intake and carefully adjusted for relevant
potential confounders. In a meta-analysis of these eight studies, we
found a stepwise reduction in breast cancer risk with increasing soy
intake. Compared to the lowest soy intake (o5mg isoflavones per
day), risk of breast cancer reduced significantly by 12% in association
with moderate intake (B10mg isoflavones per day) and 29% in
association with high intake (20 isoflavones or more per day; Wu
et al, 2008). However, only one Asian study was of cohort type
(Yamamoto et al, 2003). Assessment of soy intake was incomplete in
two other cohort studies (Key et al, 1999; Nishio et al, 2007) and they
were not included in our meta-analysis. Since the publication of our
review on soy and breast cancer, no association with soy intake was
found in a British cohort with moderate soy intake (Travis et al,
2008). Thus, additional cohort studies of soy and breast cancer risk
are needed in populations with substantial soy intake.
We have, therefore, investigated soy intake and breast cancer
risk in the Singapore Chinese Health Study (SCHS), a cohort study
of diet and cancer.
MATERIALS AND METHODS
The SCHS was a prospective investigation of the role of dietary
factors in cancer aetiology (Hankin et al, 2001). Briefly, 35303
Chinese women and 27954 Chinese men aged 45–74 years of
Hokkien or Cantonese dialect group were enrolled in the
population-based cohort study between April 1993 and December
1998. At recruitment, information on lifestyle factors, usual diet,
and reproductive history (for women only) was obtained through
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yin-person interviews. The food frequency questionnaire (FFQ)
covered usual intake during the previous 12 months of 165 items
identified in a prior 24-h recall study to represent the major food
and beverage items in this population. Frequency of consumption
was assessed using eight categories for foods and nine categories
for beverages, ranging from ‘never or hardly ever’ to ‘two or more
times per day.’ Colour photographs of portion sizes (small,
medium, and large) were used to aid with recall of amounts
consumed. A food composition table was developed, and items on
the questionnaire were linked to the food composition database.
There are seven common soy products in the Singapore Chinese
diet and all are nonfermented. We expressed total soy intake in
terms of grams of soy protein, soy isoflavones, and equivalent
amounts of tofu per day (Wu et al, 2002). Soy protein intake was
calculated using the Singapore Food Composition Table (Hankin
et al, 2001). Total soy isoflavone intake was estimated from the
summation of the genistein, daidzein, and glycitein contents that
have previously been measured in market samples of common soy
foods in Singapore. Equivalent amounts of tofu per day were
calculated to facilitate comparison with a known dietary item while
taking into account the varying water contents across the seven soy
foods. This was carried out as follows: the water content of the
various soy-containing foods varies from 54% for cooked foojook,
58% for cooked foopei, 69% for cooked taukwa, and 89% for
cooked plain tofu to 92% for soybean drink. We, therefore,
determined that 1g of cooked foojook is equivalent to 4.2g (46/11)
of plain tofu, 1g of cooked foopei is equivalent to 3.8g (42/11)
plain tofu, and so on. The total soy intake for each subject was
estimated as the summation of all soy foods expressed in units of
plain tofu equivalent. In a dietary validation study of SCHS
subjects, we found correlation coefficients of 0.63, 0.39, and 0.32
between the FFQ and a series of 24-h recalls for tofu, isoflavone,
and soy protein, respectively. Furthermore, dietary intake of soy
was statistically significantly correlated with urinary isoflavonoid
(Seow et al, 1998).
The SCHS has been continuously followed, both actively
through re-interviews and passively through computer linkage to
population-based death and cancer registries in Singapore (Seow
et al, 1996). The nationwide cancer registry has been in place since
1968 and is complete in its recording of cancer (Parkin et al, 2002).
Loss to follow-up in the cohort has been negligible.
As of 31 December 2005, 629 women had developed breast
cancer among the 34028 participants following an accumulation of
338242 person-years (1275 of the 35303 women with prevalent
cancer at baseline were excluded). Histological, staging informa-
tion, oestrogen receptor (ER), and progesterone receptor (PR)
status on all breast cancer diagnoses were confirmed by manual
review of the pathology reports and clinical charts.
Statistical analysis
Data were analysed using standard methods for cohort studies. We
calculated person-years from the baseline questionnaire to the date
of breast cancer diagnosis, death or December 31, 2005, whichever
was sooner. Proportional hazards regression methods were used to
examine the association between quartiles of isoflavone intake and
breast cancer risk, measured by relative risks (RR) and their
corresponding 95 percent confidence intervals (95% CI) in all
subjects and among those postmenopausal at baseline. Relevant
demographic factors including age (years) at recruitment, year of
recruitment (1993–1998), dialect group (Cantonese, Hokkien),
education (no formal education, primary school, secondary school,
or higher), and established risk factors including age when period
became regular (o12, 13–14, 15–16, and 17þ years or period
never became regular), number of live births (none, 1–2, 3–4, and
5þ), body mass index (BMI; continuous, kgm
 2), menopausal
status, and n-3 fatty acid intake were adjusted in the analysis. As
adjusting for green tea intake, tobacco smoking (never and ever),
alcohol intake (nondrinker, monthly, weekly, and daily), and
history of diabetes left the results unchanged; we show results
without these further adjustments. We conducted subgroup
analyses of soy isoflavone intake and risk, stratified by menopausal
status and examined the potential effect modification by including
interaction terms for body size. We also investigated the effect of
soy isoflavone intake by ER and PR status (positive, negative, and
unknown), and ER/PR status combined (positive/positive, nega-
tive/negative, and unknown/unknown). P-value less than 5% are
considered statistically significant and all P-values quoted are two-
sided.
RESULTS
The mean age of breast cancer patients at diagnosis was 62.0 years
(standard deviation (s.d.) 8.2 years; range: 46–86 years). The mean
interval between interview and diagnosis was 5.6 years (range: 1
month–12 years). Table 1 shows the association between intake of
soy isoflavone and risk. Risk was significantly reduced (adjusted
RR¼0.82, 95% CI¼0.70–0.97; P¼0.019) among women with
above median soy intake (410.6mg1000Kcal
 1) compared to
those with lower intake (o¼10.6mg1000Kcal
 1). Results were
unchanged after adjustment for intake of green tea, tobacco
smoking, alcohol intake, and history of diabetes (data not shown).
Table 1 also shows the associations stratified by menopausal status
at enrollment. Soy intake was unrelated to risk in premenopausal
women (RR¼1.04, P¼0.82), but was significantly inversely
associated with risk in postmenopausal women with an adjusted
RR for those above the median of 0.74 (95% CI¼0.61–0.90; P for
interaction¼0.078).
The inverse association between soy intake and breast cancer
was statistically significant in postmenopausal women with higher
(above median value for all women in the cohort) BMI (adjusted
RR¼0.67, 95% CI¼0.51–0.88) but not in those below the median
BMI value (adjusted RR¼0.83, 95% CI¼0.62–1.11) (Table 2). The
two sets of RRs were not statistically different from each other
(P for interaction¼0.29). Table 3 shows that there were no
material differences in the relationship with soy by hormone
receptor status in postmenopausal women.
The protective effect of high soy intake was very clear and
statistically significant among women with 10 or more years of
follow-up (RR¼0.48, 95% CI¼0.29–0.78) (Table 4). High soy
intake was less strongly associated with risk reduction among
Table 1 Intake of soy isoflavones and breast cancer risk
Soy isoflavone
(mg1000kcal
 1)
Number of
cases Person-years RR
a 95% CI
All subjects
o10.6mg 339 167312 1.00
X10.6mg 290 170930 0.82 0.70–0.97
P-value 0.019
Menopausal status at baseline
Premenopausal
o10.6mg 84 43668 1.00
X10.6mg 106 52937 1.04 0.77–1.40
P-value 0.82
Postmenopausal
o10.6mg 255 123608 1.00
X10.6mg 184 117960 0.74 0.61–0.90
P-value 0.003
P interaction 0.08
aAdjusted for age, years of interview, dialect, education, family history of breast
cancer, parity, age when period became regular, menopausal status (if applicable),
body mass index, and n-3 fatty acid.
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CI¼0.74–1.05). Results were similar when we restricted the
analysis to postmenopausal women (Table 4).
DISCUSSION
This study found a significant 18% reduction in breast cancer risk in
association with the above median soy isoflavone intake (X10.6mg
1000Kcal
 1), a degree of risk reduction compatible with the results that
we found in a combined analysis of eight studies in Asian populations
with soy intake (Wu et al, 2008). The amount of soy isoflavones
(B10mg per day) implicated to have benefit in cancer prevention can
be obtained in one standard serving of tofu (Trock et al, 2006). The
inverse association with soy intake in this Singapore cohort was
statistically significant in postmenopausal but not in premenopausal
women (Table 1), but we were limited in studying such women by
the lower age limit of this cohort study being 45 years, and only 26%
of participants were aged 45–50 years at enrollment. There is a
suggestion that heavier postmenopausal women showed a stronger
association than leaner women, although the two sets of RRs are not
statistically different from each other (Table 2). The risk reduction
with soy intake was found in both ERþ and ER  tumours as well as
in PRþ and PR  tumours (Table 3). A stronger soy–breast cancer
association was found among women with longer (10þ years)
duration of follow-up (Table 4).
To date, eight cohort/nested case–control studies have inves-
tigated the association between soy intake and breast cancer risk,
of which four were not very informative, being conducted in
western populations with very low soy intake (average of B1mgof
soy isoflavones per day). Of these, no association was found in
three studies in populations with very low soy intake (Horn-Ross
et al, 2002; Keinan-Boker et al, 2004; Touillaud et al, 2006),
whereas one study found an increased risk (Grace et al, 2004).
The other four cohort studies were in populations with
moderate-to-high soy intake, one in the Oxford arm of the
European Prospective Investigation into Cancer and Nutrition
(EPIC-Oxford), one of the few non-Asian populations with
moderate soy intake. The mean daily soy isoflavone intake was
2.9mg among non-vegetarians and 10.2mg among vegetarians, but
only about 30% of the 37643 cohort participants were vegetarians,
limiting the investigation of this question (Travis et al, 2008).
Three studies were conducted in Japan (Key et al, 1999; Yamamoto
et al, 2003; Nishio et al, 2007) with high soy intake. Our finding of
a significant inverse association between soy intake and breast
cancer, particularly in postmenopausal women is similar to that
reported in the Japan Public Health Center-Based Prospective
Study (JPHC) (Yamamoto et al, 2003). Soy intake in the JPHC
study was obtained using a validated FFQ including intake of five
soy foods, covering approximately 90% of the total soy isoflavone
intake in Japan (Yamamoto et al, 2001). In contrast, breast cancer
risk was unrelated to soy intake in two other Japanese cohort
studies (Key et al, 1999; Nishio et al, 2007); assessment of soy
intake was less complete in both studies and considerable random
misclassification of soy exposure is likely to have led to under-
estimation of risk (ie, bias towards the null).
After the menopause, adipose tissue is the major site for
oestrogen synthesis and high body size is associated with the
elevated endogenous oestrogen (Judd et al, 1982). We noted a
stronger association among postmenopausal women with below vs
above median BMI, although the two sets of RRs were not
statistically different from each other. In a case–control study
among women in Shanghai, China, the inverse association was
more evident in women with higher BMI (25þ kgm
 2) than
women with lower BMI irrespective of menopausal status (Dai
et al, 2001). In the four cohort studies reviewed in the previous
paragraph, the soy–breast cancer association was not examined
separately by BMI category.
Our results show comparable effects of soy on ERþ and ER 
tumours as well as PRþ and PR  tumours (Table 3). Of the eight
studies included in our meta-analysis on soy and breast cancer in
Table 2 Intake of soy isoflavones and breast cancer risk in postmeno-
pausal women by body mass index
Soy isoflavone
(mg/1000kcal)
Number
of cases Person-years RR
a 95% CI
BMI below median (p24kgm
 2)
o10.6mg 110 59587 1.00
X10.6mg 90 57772 0.83 0.62–1.11
P-value 0.21
BMI above median (424 kgm
 2)
o10.6mg 145 64021 1.00
X10.6mg 94 60187 0.67 0.51–0.88
P-value 0.004
P interaction 0.29
aAdjusted for age, years of interview, dialect, education, family history of breast
cancer, parity, age when period became regular, body mass index, and n-3 fatty acid.
Table 3 Intake of soy isoflavones and breast cancer risk (RR, 95% CI)
a in postmenopausal women by oestrogen receptor (ER) and progesterone receptor
(PR) status
Soy isoflavone
(mg1000kcal
 1) Person-years
Hormone receptor
(positive)
Hormone receptor
(negative)
Hormone receptor
(unknown)
N ERþ N ER  N ER DK
o10.6mg 122868 111 1.00 56 1.00 88 1.00
X10.6mg 117370 73 0.67 (0.49–0.91) 36 0.66 (0.42–1.02) 75 0.89 (0.64–1.22)
P-value 0.01 0.06 0.46
N PRþ N PR  N PR DK
o10.6mg 122667 77 1.00 87 1.00 91 1.00
X10.6mg 117264 53 0.69 (0.48–1.00) 56 0.67 (0.47–0.95) 75 0.85 (0.62–1.17)
P-value 0.047 0.02 0.32
N ER+PRþ N ER PR  N ER & PR DK
b
o10.6mg 122651 74 1.00 51 1.00 88 1.00
X10.6mg 117262 52 0.70 (0.48–1.01) 35 0.70 (0.45–1.10) 75 0.89 (0.64–1.22)
P-value 0.060 0.12 0.46
aAdjusted for age, years of interview, dialect, education, family history of breast cancer, parity, age when period became regular, body mass index, and n-3 fatty acid.
bWe did not
include breast cancers that were ER+ PR  (n¼57), ER+PR unknown (n¼1), ER PR+ (n¼4) or ER–PR unknown (n¼2) in the analysis.
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analysis investigated the risk by hormone receptor status, finding
the effect more apparent for tumours that were positive for both
ER and PR (Dai et al (2001). Further investigation of the soy–
breast cancer association by menopausal status and ER/PR status
will be needed.
Three studies (Shu et al, 2001; Wu et al, 2002; Thanos et al,
2006), including a case–control study that we conducted among
Asian American women in Los Angeles County, found that the
timing of soy exposure is an important codeterminant of risk, with
stronger effects from exposures at earlier ages. This study lends
further support to soy exposures occurring during the earlier
stages of carcinogenesis and would result in a greater degree of
reduction in a woman’s subsequent risk for breast cancer. We
noted that the magnitude of risk reduction among women with 10
or more years between exposure assessment and cancer diagnosis
was twice than that among their counterparts with shorter time
intervals. Interestingly, this model may explain the seemingly
contradictory findings from recent soy intervention studies with
generally null findings (Maskarinec et al, 2004; Wu et al, 2005).
This prospective study has several important strengths. First,
information on soy intake and other risk factors was obtained in-
person before cancer diagnosis and thus the recall bias is not a
concern. This is particularly important as seven of the eight studies
in our meta-analysis on soy and breast cancer were case–control
studies (Wu et al, 2008). Second, we used a validated FFQ, our
assessment of soy intake was relatively complete, and dietary
intake of soy was statistically significantly correlated with urine
isoflavone levels (Seow et al, 1998). Third, our study is larger than
previous cohort studies on this topic (two of the previous studies
had less than 200 breast cancer cases (Yamamoto et al, 2003;
Nishio et al, 2007). The larger sample size, particularly of
postmenopausal women, has allowed us to investigate the potential
modifying effect of body size on the soy–breast cancer association
in postmenopausal women. Finally, we were able to examine the
risk pattern by hormone receptor status, apparently the first such
from a prospective study.
In summary, among 34028 women in the SCHS, high soy intake
(X10.6mg isoflavones per 1000Kcal) was associated with a
significant 18% reduction in breast cancer risk. Our results adds
to the compelling results obtained from case–control studies on
soy and breast cancer and suggest that the soy isoflavones may
have lasting beneficial effects against breast cancer development.
The level of soy isoflavones implicated to have benefit (B10mg
isoflavones per day or one standard serving of tofu) is achievable
even in populations that do not typically eat soy foods.
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